Tag Archives: ATTR amyloidosis

January, 2018

December, 2017

September, 2017

  • 20 September

    Alnylam’s Rare Disease Drug Meets Endpoints in Late-Stage hATTR Amyloidosis Study

    CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint …